Open Collections

UBC Faculty Research and Publications

Atomoxetine for ADHD in children and adolescents Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 73 summarizes the evidence for atomoxetine for Attention-Deficit/Hypertactivity Disorder (ADHD) in children and adolescents. Conclusions: Short-term use (< 1 year): Based on RCTs < 8 weeks, atomoxetine reduces teacher and parent ratings of hyperactive/impulsive disruptive behaviour but the effect is less than that seen with methylphenidate and mixed amphetamine salts. Atomoxetine causes the following adverse effects in 5 to 15% of patients: decreased appetite, abdominal pain, vomiting and somnolence. Intermediate- to long-term use (>1 year): No RCTs are available. Effects on educational achievement are unknown. Atomoxetine adversely affects growth (weight and height) compared to national norms. Adverse consequences of the increased heart rate and blood pressure caused by atomoxetine are expected based on epidemiologic data.

Item Metadata

Title
Atomoxetine for ADHD in children and adolescents
Alternate Title
Therapeutics Letter 73
Creator
Therapeutics Initiative (University of British Columbia)
Date Issued
2009-03
Description
Therapeutics Letter 73 summarizes the evidence for atomoxetine for Attention-Deficit/Hypertactivity Disorder (ADHD) in children and adolescents. Conclusions: Short-term use (< 1 year): Based on RCTs < 8 weeks, atomoxetine reduces teacher and parent ratings of hyperactive/impulsive disruptive behaviour but the effect is less than that seen with methylphenidate and mixed amphetamine salts. Atomoxetine causes the following adverse effects in 5 to 15% of patients: decreased appetite, abdominal pain, vomiting and somnolence. Intermediate- to long-term use (>1 year): No RCTs are available. Effects on educational achievement are unknown. Atomoxetine adversely affects growth (weight and height) compared to national norms. Adverse consequences of the increased heart rate and blood pressure caused by atomoxetine are expected based on epidemiologic data.
Subject
Adolescent; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Methylphenidate
Genre
Other
Type
Text
Language
eng
Notes
The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available
2023-06-20
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
DOI
10.14288/1.0433652
URI
http://hdl.handle.net/2429/85062
Affiliation
Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International